FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
1,276 letters match. Newest first.
-
DrugsYangzhou Sion Commodity Co., Ltd.
FDA warned Yangzhou Sion Commodity over drug manufacturing failures, including untested high-risk ingredients and unreliable lab records.
High risk -
DrugsAnnovex Pharma, Inc.
FDA warns outsourcing facility Annovex Pharma in Lorton, VA, over contaminated sterile drug production and missed FDA reports.
High risk -
DrugsAspen Biopharma Labs Private Limited
FDA warns Aspen Biopharma Labs over current good manufacturing practice failures in active ingredient manufacturing after U.S. recall.
High risk -
DrugsHangzhou Glamcos Biotech Co., Ltd.
Hangzhou Glamcos Biotech’s OTC antibacterial wipes had CGMP violations and were unapproved and misbranded, FDA says.
High risk -
DrugsAdvanced Pharmaceutical Technology
FDA warns Advanced Pharmaceutical Technology over drug manufacturing quality failures, sterility controls, and unapproved drugs.
High risk -
DrugsNeva Global Grup Sanayi Ic Ve Dis Ticaret Anonim Sirketi
FDA warns Turkish OTC drug maker Neva Global over inadequate component testing, process validation, stability, and quality oversight.
High risk -
DrugsKabana Skin Care
FDA warned Kabana Skin Care that its "Kabana Body Wash +UV" is an unapproved, misbranded sunscreen drug sold without required FDA clearance.
Medium -
DrugsWaxhead Sun Defense Company
FDA warned Waxhead Sun Defense Company that its zinc body wash/shampoo is an unapproved, misbranded OTC sunscreen drug.
Medium -
DrugsCoLabs Intl. Corp
CoLabs Intl. Corp marketed KLĒNSKIN WASH ON SUNSCREEN, an OTC sunscreen wash, without an FDA-approved application or authorized dosage form.
Medium -
DrugsInternational Laboratories Corp
FDA warned International Laboratories Corp, a Thai drug manufacturer, over fabricated lab records and inadequate CGMP controls.
High risk -
DrugsMehran Michael Bahrami, M.D.
FDA warns clinical investigator Dr. Mehran Michael Bahrami over protocol violations and missing records in investigational drug trials.
High risk -
DrugsAspen Pharmacare Holdings Limited
FDA warns Aspen subsidiary over sterile OTC drug manufacturing failures including impurity testing, aseptic practices, data integrity, and environmental monitoring.
High risk -
DrugsRite-Kem Incorporated
FDA warned Rite-Kem over inadequate current good manufacturing practice testing of over-the-counter drugs, including hand sanitizers and antimicrobial products.
High risk -
DrugsVegewax Candleworx Ltd.
FDA warns Vegewax Candleworx over CGMP violations in OTC drug manufacturing, including inadequate component testing and OOS investigations.
High risk -
DrugsPico IV Inc.
FDA warned Pico IV Inc. that its intravenous CBD product Pico IV is an unapproved new drug sold with drug claims.
High risk -
DrugsC & A Naturistics
C & A Naturistics sold unapproved new drugs online, including AK Forte with hidden acetaminophen and diclofenac.
High risk -
DrugsFiller Lux dba Filler Lux USA
FDA warned Filler Lux USA that it sells unapproved injectable lipolytic drugs online without FDA approval.
High risk -
DrugsFox Pharma LLC
FDA warned Fox Pharma LLC that it sells unapproved injectable lipolytic drugs online.
High risk -
DrugsHyaluron Pen Store, LLC dba Glow Nest Beauty
Glow Nest Beauty sells unapproved injectable fat-dissolving drugs online, FDA warned.
High risk -
DrugsJulian Naya Beauty LLC
FDA warned Julian Naya Beauty LLC that it sells six unapproved injectable fat-dissolving drugs on its website and social media.
High risk -
DrugsVivid-Scientific LLC
Vivid-Scientific LLC sold injectable fat-dissolving products online as unapproved new drugs without FDA-approved applications.
High risk -
DrugsAmazon.com, Inc.
FDA warned Amazon over selling unapproved injectable fat-dissolving drugs on its website.
High risk -
DrugsShree Jaya Laboratories PVT. LTD.
FDA warned Shree Jaya Laboratories after an inspection found CGMP deviations in API and intermediate manufacturing, including dirty equipment and torn batch records.
High risk -
DrugsUSApeptide.com
FDA warns Germany-based USApeptide.com that it sells unapproved and misbranded semaglutide and tirzepatide drugs to U.S. consumers online.
High risk -
DrugsLinghai ZhanWang Biotechnology Co., Ltd
Linghai ZhanWang Biotechnology's OTC drugs, including antimicrobial wipes, fail manufacturing quality rules; FDA cites missing tests.
High risk -
DrugsRight Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals
FDA warned outsourcing facility Carie Boyd Pharmaceuticals in Irving, TX that sterile drug production had airflow, media fill and contamination control failures.
High risk -
DrugsProRx, LLC
FDA warns ProRx, LLC about insanitary sterile compounded-drug production and manufacturing-quality failures.
High risk -
DrugsGranules India Limited
FDA warned Granules India in Telangana, India, that its finished drugs are adulterated after inspectors found cross-contamination in air ducts, bird droppings and torn records.
High risk -
DrugsTKTX USA
FDA warned TKTX USA that its TKTX Numbing Creams are unapproved and misbranded drugs with lidocaine levels above OTC limits.
High risk -
DrugsTKTX Numb Store
FDA warned TKTX Numb Store that its lidocaine anesthetic creams are unapproved and misbranded drugs sold without a prescription.
High risk -
DrugsTKTX Store
FDA warns TKTX Store it sells unapproved lidocaine and prilocaine numbing creams online for tattooing and cosmetic procedures.
High risk -
DrugsTKTX Numbing Cream USA
FDA warned TKTX Numbing Cream USA that its lidocaine numbing creams are unapproved and misbranded new drugs.
High risk -
DrugsChem-Tech, Ltd.
Chem-Tech, Ltd. lacked adequate investigations and clean equipment for its OTC drug.
High risk -
DrugsZenzi Pharmaceutical Industries Pvt. Ltd.
Zenzi Pharmaceutical Industries refused FDA requests for records about prescription drugs made for the U.S. market.
High risk -
DrugsMarshalls Traditional Healthcare CC
Marshalls Traditional Healthcare, an OTC drug maker in South Africa, lacked finished-product release testing and process validation.
High risk -
DrugsABR Laboratory LLC
FDA warned ABR Laboratory, a contract drug testing lab, that unverified microbial test methods and missed investigations made tested drugs adulterated.
High risk -
DrugsTyche Industries Ltd
FDA warned Tyche Industries over falsified records, dirty equipment, and untested raw materials at its API plant.
High risk -
DrugsJagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals cited for API CGMP and listing failures after Indian inspection, leading to US import alert.
High risk -
DrugsAmWiner & Raphe Holdings, LLC dba rapheGenerics Corp
FDA cited rapheGenerics for manufacturing-quality failures and unapproved minoxidil hair regrowth drugs.
High risk -
DrugsChengdu Innovation Pharmaceutical Co., Ltd.
FDA warned Chengdu Innovation Pharmaceutical over CGMP (manufacturing quality rules) failures in API (drug ingredient) manufacturing, including no identity testing of incoming materials.
High risk -
DrugsWuhu Nuowei Chemistry Co., Ltd.
FDA cited Wuhu Nuowei Chemistry for API CGMP deviations in impurity testing, stability data, and cleaning, and placed products on import alert.
High risk -
DrugsISOThrive, Inc.
ISOThrive ran two human studies of a supplement used as a drug without submitting a required IND.
High risk -
DrugsStrukmyer LLC dba Strukmyer Medical
Strukmyer Medical was cited for current good manufacturing practice violations after FDA found repeated microbial contamination in water used to make OTC drugs.
High risk -
DrugsShantou Kangjie Daily Chemical Industry Co., Ltd
FDA warns Shantou Kangjie over CGMP failures for OTC drugs, including untested ethanol and no quality unit.
High risk -
DrugsImperial Palace Commodity -Dongguan- Co., Ltd.
FDA warns Chinese maker of OTC alcohol wipes that weak component testing and process validation make its drugs adulterated.
High risk -
DrugsCenter for Instrumental Analysis of China Pharmaceutical University
Center for Instrumental Analysis of China Pharmaceutical University cited for incomplete API testing records and no quality unit.
High risk -
DrugsGlobal Calcium Pvt. Limited
FDA cites Global Calcium API plant for falsified records, deleted files, facility leaks and incomplete impurity profiles; products on Import Alert 66-40.
High risk -
DrugsFagron Compounding Services, LLC dba Fagron Sterile Service
FDA warns Fagron Sterile Services about unsafe sterile drug production and labeling problems at its Wichita facility.
High risk -
DrugsKardesler Ucan Yaglar Sanayi Anonim Sirketi
Turkey-based OTC drug maker Kardesler Ucan failed to test glycerin, propylene glycol and ethanol for dangerous impurities and is on US import alert.
High risk -
DrugsMihon Corp. d/b/a VitalityVita and Boulla, LLC
FDA warns Mihon Corp./Boulla that VitalityXtra, PeakMax, ZapMax and ZoomMax supplements contain hidden sildenafil and diclofenac and are unapproved, misbranded drugs.
High risk